Cargando…

Idarucizumab for dabigatran reversal in cardiac tamponade complicating percutaneous intervention in ST elevation myocardial infarction

An 83-year-old man with a history of permanent atrial fibrillation (AF) anticoagulated by dabigatran 150 b.i.d., type 2 diabetes mellitus, and hypertension was admitted to the hospital with a diagnosis of ST-elevation myocardial infarction (STEMI). The patient was loaded with 300 mg of aspirin p.o.,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurdziel, Marta, Hudzik, Bartosz, Kazik, Anna, Piegza, Jacek, Szkodziński, Janusz, Gąsior, Mariusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2021
Materias:	Image in Intervention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039931/ https://www.ncbi.nlm.nih.gov/pubmed/33868433 http://dx.doi.org/10.5114/aic.2021.104784

Ejemplares similares

COVID-19 mimicking ST-elevation myocardial infarction
por: Bujak, Kamil, et al.
Publicado: (2020)

Imaging-guided percutaneous coronary intervention with ultra-low contrast angiographic control for patients at extreme risk of contrast induced nephropathy
por: Pyka, Łukasz, et al.
Publicado: (2020)

Prognostic impact of multimorbidity in patients with type 2 diabetes and ST-elevation myocardial infarction
por: Hudzik, Bartosz, et al.
Publicado: (2017)

Idarucizumab: A novel antidote for reversal of dabigatran
por: Rehman, Abdul, et al.
Publicado: (2016)

Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage
por: Balakumar, Jonathan, et al.
Publicado: (2017)

Use of idarucizumab for dabigatran reversal in cardiac tamponade during atrial fibrillation ablation: A case report
por: Yoshizawa, Tomoharu, et al.
Publicado: (2019)

Survival benefit from recent changes in management of men and women with ST-segment elevation myocardial infarction treated with percutaneous coronary interventions
por: Zandecki, Łukasz, et al.
Publicado: (2019)

The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
por: Glund, Stephan, et al.
Publicado: (2018)

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
por: Sié, Pierre
Publicado: (2016)

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019)

Idarucizumab for the treatment of dabigatran-related nephropathy
por: Alsamarrai, Ammar, et al.
Publicado: (2020)

Case Report: do heart transplant candidates benefit from mechanically supported revascularization?
por: Pyka, Lukasz, et al.
Publicado: (2023)

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
por: Kafke, Waldemar, et al.
Publicado: (2016)

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
por: Proietti, Marco, et al.
Publicado: (2018)

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
por: Abdulrehman, Jameel, et al.
Publicado: (2021)

The impact of type 2 diabetes mellitus on prognosis in patients with non-ST elevation myocardial infarction
por: Birkner, Katarzyna, et al.
Publicado: (2017)

CHA(2)DS(2)-VASc score is useful in predicting poor 12-month outcomes following myocardial infarction in diabetic patients without atrial fibrillation
por: Hudzik, Bartosz, et al.
Publicado: (2016)

Safety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab
por: Riario Sforza, Gian Galeazzo, et al.
Publicado: (2018)

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke
por: Hieber, Maren, et al.
Publicado: (2019)

Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
por: Gendron, Nicolas, et al.
Publicado: (2017)

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
por: Norris, Stephen, et al.
Publicado: (2017)

Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature
por: Frol, Senta, et al.
Publicado: (2021)

Double stent loss during multivessel percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome
por: Hawranek, Michał, et al.
Publicado: (2014)

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
por: Held, Valentin, et al.
Publicado: (2016)

Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma
por: Edwards, Gail, et al.
Publicado: (2017)

First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab
por: Song, Steven, et al.
Publicado: (2017)

Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report
por: Tralhão, António, et al.
Publicado: (2017)

Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
por: Ströhle, Mathias, et al.
Publicado: (2021)

Idarucizumab reverses dabigatran-induced anticoagulation in treatment of gastric bleeding: A case report
por: Jia, Yu, et al.
Publicado: (2022)

Deferred Stenting for Heavy Thrombus Burden During Percutaneous Coronary Intervention for ST-Elevation MI
por: Pradhan, Akshyaya, et al.
Publicado: (2021)

Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report
por: Mutzenbach, Johannes Sebastian, et al.
Publicado: (2016)

Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
por: Binet, Quentin, et al.
Publicado: (2018)

Reversal of Anticoagulation Effect of Dabigatran with Idarucizumab, for Thrombolysis in Acute Ischemic Stroke: Inimicus Inimico Amicus
por: Maramattom, Boby V., et al.
Publicado: (2019)

Idarucizumab (Praxbind(®)) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients
por: Kalmanovich, Eran, et al.
Publicado: (2021)

Intravenous Thrombolysis After Reversal of Dabigatran With Idarucizumab in Acute Ischemic Stroke: A Case Report
por: Xie, Dan, et al.
Publicado: (2021)

Dabigatran Toxicity in Acute Kidney Injury: Hemodialysis and Idarucizumab Required
por: McBride, Lucy, et al.
Publicado: (2018)

Idarucizumab for a traumatic head injury patient taking dabigatran
por: Maruyama, Shuhei, et al.
Publicado: (2018)

Is ST-segment elevation myocardial infarction always a simple diagnosis?
por: Zalas, Krzysztof, et al.
Publicado: (2023)

Dabigatran level monitoring prior to idarucizumab administration in patients requiring emergent cardiac surgery
por: Litwinowicz, Radoslaw, et al.
Publicado: (2017)

Single nucleotide polymorphisms for genes encoding cytokines in the context of cardiac surgery. Part I: Heart transplantation
por: Danikiewicz, Aleksander, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7o07d1eks66fhqcnv47kt26aci